Eligible consumers and third-party payers who purchased certain generic drugs in the United States between May 1, 2009, and December 31, 2019, can now file claims to receive a share of $533 million in class action settlements. A federal court has granted final approval for the settlements, allowing Settlement Class Members to submit claim forms to recover overpayments allegedly caused by antitrust violations. The settlements involve Sun Pharmaceutical , Sandoz Inc., Apotex Corp., and Heritage Pharmaceuticals Inc., among others, in the lawsuit In re Generic Pharmaceuticals Antitrust Litigation.

The lawsuit alleges that generic manufacturers violated federal and state antitrust laws, consumer protection statutes, and common law, causing End-Payers (EPPs) to pay inflated prices. The Settling Defendants deny any wrongdoing, and the litigation continues against Non-Settling Defendants. Four EPP Settlement Classes have been certified, one for each settlement, covering Consumers and Third-Party Payers such as insurers or employers with self-funded plans. The settlements exclude Indiana, Ohio, and certain entity types.

Settlement Breakdown

The total settlement fund of $533 million comprises contributions from multiple manufacturers to resolve consumer and Third-Party Payer claims. The following table details the amounts paid by each settling entity:

After deducting notice and administration costs, attorney's fees, and litigation expenses, the remaining funds will be distributed proportionally to valid claimants. Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A., Inc. are collectively referred to as Sun/Taro in the settlement agreement.

How to File a Claim

To receive a payment, eligible class members must submit a claim form with supporting documentation. Claims can be filed online at the EPP Settlement Website or via a paper form postmarked by the deadline. The deadline for submission is November 9, 2026. Claimants do not need to sign up with a claims recovery firm or pay an additional law firm to participate.

Payment amounts depend on the total number of valid claims received and the claimant's documented spending on the Named Generic Drugs during the specified period. Failure to submit a claim form by the deadline will result in the forfeiture of any settlement benefits. Detailed information on the specific drugs included, class definitions, and claim procedures is available on the settlement website.

Sun Pharmaceutical Industries Limited has announced that its 34th Annual General Meeting (AGM) will be held on Friday, July 31, 2026, at 4:00 p.m. IST via video conferencing. The company has completed the dispatch of the notice for the 34th AGM along with the annual report for the financial year 2025-26 to all shareholders whose email addresses are registered with the Registrar and Transfer Agent, MUFG Intime India Private Limited, or with depository participants. The documents are also available on the company's website and the websites of BSE Limited and the National Stock Exchange of India Limited.

The company has provided a facility for shareholders to cast their votes electronically through remote e-voting. The remote e-voting period commences on Monday, July 27, 2026, at 9:00 a.m. IST and concludes on Thursday, July 30, 2026, at 5:00 p.m. IST. Shareholders holding shares in dematerialized form can log in via the CDSL Easi/Easiest facility or NSDL DeAS facility, while those holding physical shares or non-individual shareholders can access the e-voting website using their DPID/Client ID or Folio Number. Detailed instructions are available under the 'Investor Services' section on the company's website.

Only shareholders whose names are recorded in the Register of Members or the Register of Beneficial Owners as of the cut-off date, Friday, July 24, 2026, are entitled to avail the remote e-voting facility or vote at the AGM. Shareholders who have cast their vote by remote e-voting prior to the meeting may attend the AGM but will not be permitted to vote again. Those who become shareholders after the dispatch of the notice but hold shares as of the cut-off date may generate login credentials by following the guidelines provided on the company's website.

The company has emphasized the importance of updating Know Your Customer (KYC) details for shareholders holding shares in physical form. As per a SEBI circular dated June 10, 2024, shareholders must update their PAN, contact details, nomination, bank account details, and specimen signature. Failure to meet these KYC requirements, excluding the non-submission of a choice of nomination, will result in an inability to receive dividends. Shareholders holding shares in demat form must contact their depository participants to update their details.

In the event of queries or grievances regarding attending the AGM or e-voting, shareholders may refer to the FAQs and e-voting manual available at www.evotingindia.com . They may also contact Mr. Rakesh Dalvi, Senior Manager at Central Depository Services (India) Limited, via email at helpdesk.evoting@cdsindia.com or call the toll-free number 1800 21 09911.

Key Dates for Sun Pharmaceutical Industries Limited 34th AGM